ENDRA Life Sciences Inc. (NDRA)

ENDRA Life Sciences Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar 31, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	0.36	0.76	3.23	2.83	4.89	9.46
Cash & Short-Term Investments	0.36	0.76	3.23	2.83	4.89	9.46
Cash Growth	-82.74%	-76.39%	13.96%	-42.04%	-48.33%	30.91%
Inventory	-	-	-	2.62	2.64	1.28
Other Current Assets	0.18	0.21	0.2	0.2	0.49	1.35
Total Current Assets	0.54	0.97	3.43	3.03	5.38	12.09
Net Property, Plant & Equipment	0.46	0.5	0.65	0.47	0.74	0.77
Other Long-Term Assets	2.44	2.38	0.37	0.63	0.51	0.01
Total Assets	3.44	3.85	4.45	6.75	9.27	12.87
Accounts Payable	-	-	-	0.7	1.52	1.41
Short-Term Debt	-	-	-	0.03	0.03	-
Current Portion of Leases	0.13	0.13	0.1	0.17	0.15	0.13
Total Current Liabilities	0.13	0.13	0.1	0.9	1.7	1.54
Long-Term Debt	-	-	-	-	-	0.03
Long-Term Leases	0.33	0.36	0.49	0.19	0.37	0.52
Other Long-Term Liabilities	0.49	0.48	0.8	-	-	-
Total Long-Term Liabilities	0.82	0.84	1.29	0.19	0.37	0.55
Total Liabilities	0.95	0.97	1.38	1.1	2.07	2.09
Preferred Stock	-	-	-	0	0	0
Common Stock	-	-	-	0	0	0
Additional Paid-in Capital	-	-	-	97.59	89.07	79.47
Retained Earnings	-	-	-	-91.93	-81.87	-68.69
Shareholders' Equity	1.79	2.26	2.56	5.66	7.2	10.78
Total Liabilities & Equity	3.44	3.85	4.45	6.75	9.27	12.87
Total Debt	0.46	0.49	0.58	0.39	0.55	0.68
Net Cash (Debt)	-0.1	0.27	2.65	2.44	4.34	8.78
Net Cash Growth	-	-89.79%	8.43%	-43.82%	-50.56%	34.25%
Net Cash Per Share	-0.11	0.34	13.09	670.93	2628.34	7511.48
Book Value	1.79	2.26	2.56	5.66	7.2	10.78
Book Value Per Share	1.89	2.87	12.67	1556.38	4360.64	9223.45
Tangible Book Value	1.79	2.26	2.56	5.66	7.2	10.78
Tangible Book Value Per Share	1.89	2.87	12.67	1556.38	4360.64	9223.45

Updated May 15, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q